This week at GRC Bioorganic Chemistry, Eddie Ray Watts and Spurti Akki are presenting two aspects of how we leverage our TherML™ platform for small molecule discovery using high-throughput chemistry and ML. 6/9 Talk at 8:30 PM: "Applications of High-Throughput Chemistry in Machine Learning" 6/11 Poster at 4 PM: "Strand and DEL-iver: Innovative DEL Architectures for Hit Discovery and Lead Optimization" #GRC2026 #DrugDiscovery #MachineLearning #DEL

Today we shared new data from our CTRO-1013 program at #ADA2026 showing that liver-targeted silencing of IRS1 significantly reduced injury-associated circulatory biomarkers in an industry-standard fibrogenic preclinical mouse model, with effects that appear partly independent of reductions in liver fat. insitro’s Santhosh Satapati: “What began as a human genetics signal has become a liver-targeted MASH candidate advancing toward the clinic. With CTRO-1013, we see the potential to address both liver fat and fibrosis-relevant biology — two key dimensions of disease progression.” Additional mechanistic and histological analyses are ongoing. insitro is continuing IND-enabling studies for CTRO-1013 and expects the program to enter first-in-human clinical trials this year. Read our news release to learn more about how we applied AI-derived liver fat and fibrosis phenotypes from multimodal human data to identify causal targets, such as IRS1. insitro.com/news/insitro-pre… #MASH #DrugDiscovery #MachineLearning

Life is not defined by sameness. It comes into focus through variation — in gradients, clusters, rare signals and hidden patterns that can open new ways of seeing. At insitro, we celebrate the beauty of difference this Pride Month. We recognize that diversity enables a deeper understanding — within biology, throughout discovery, and among one another. #insitroPride

Pipeline update: insitro is in Boston this week at the 5th Annual ALS Drug Development Summit, where we will share in vivo data from our fully owned and controlled ALS oligonucleotide program for the first time. insitro’s Shababa Masoud will present in vivo gene knockdown and drug exposure data from our ALS-1 ASO program, which targets a key protein implicated in mRNA modulation. insitro’s ALS program is powered by the Virtual Human™ – our AI model of causal biology that mapped disease drivers linked to TDP-43 dysfunction and mislocalization, a pathology hallmark in ~97% of ALS patients, including aberrant cryptic exon inclusion in critical neuronal transcripts like UNC13A, STMN2, and multiple others. This platform is the foundation for our therapeutic portfolio being advanced with Bristol Myers Squibb. If you’re attending this intimate gathering of world-leading ALS drug developers, don’t miss insitro senior scientists: Shababa Masoud delivering the talk "Machine Learning Enabled ALS-Target Discovery and Development of an Oligonucleotide Therapeutic" (Thursday) Cynthia Hao presenting the poster "Paired Optical and Transcriptional Screening for ALS Targets in a TDP-43 Depleted iPSC-Derived Motor Neuron Model” (Wednesday) insitro is proud to participate in the 5th Annual ALS Drug Development Summit and share our latest research with drug developers working tirelessly toward a cure for ALS. See you in Boston! #ALS #DrugDiscovery #AI

@DaphneKoller describes her pioneering research on machine learning for probabilistic models as a @Stanford Professor, and her move to industry, where she is currently CEO of @Insitro applying ML to human biology. youtube.com/watch?v=DReHVP8r…

Very excited to be at #ICLR in Rio 🇧🇷! I'll be around all week and am happy to chat about AI for Biology / Drug Discovery. Also, my team at @insitro is hiring (jobs.ashbyhq.com/insitro/bd6…)!!! DMs are open, so feel free to reach out 😁.

Learn how @insitro’s unique team structure brings different disciplines together for more effective communication - helping it identify the most interesting problems to solve. @insitro founder @DaphneKoller shares what to co .. rt @wef

insitro founder and CEO @DaphneKoller joins industry R&D leaders today at the rEVOLUTION Symposium in Washington, D.C. – organized by @5amVentures, @BioCentury, @VersantVentures and @wilsonsonsini – for “AI in Drug Discovery: Separating Signal from Science Fiction.” Daphne is featured alongside executive and R&D leadership from @TakedaPharma, @IsomorphicLabs, and @Xaira_Thera, with @FionaHMarshall (Novartis) moderating. This timely discussion will explore what AI is enabling in practice today, as well as the technical and scientific constraints that still need to be addressed to drive impact across R&D. That is exactly what insitro was built to do. By integrating machine learning with large-scale human data and experimental systems, we capture the true complexity of disease biology to support reliable translation into therapeutic programs. We look forward to Daphne sharing how this approach is rebuilding drug discovery from an unpredictable journey into an industrialized, repeatable process to bring better drugs faster to the patients who can benefit most. → Learn more at revolution.wsgrevents.com/

"We had to build this at scale. We had to build this across biologically relevant, human-relevant systems. We had to do it at incredible quality so that the AI doesn't get trapped in things that are artifacts, as opposed to signal." insitro founder and CEO @DaphneKoller spoke with @ben_guggenheim of @washingtonpost this week on AI in drug discovery, discussing the drive to build insitro’s Virtual Human™ — described by Daphne as "a first-of-its-kind platform for making at-scale interventions in cellular systems" — to reveal how disease begins, progresses, and can be resolved. On when AI in biology became possible: "Look, all of the human feature engineering in the world is going to get totally eaten up if you have enough data for the machine to learn on its own. And that's the right path." Cellular data caught up first: "The application of truly unbounded potential in AI as applied to biology began when we started to get to the scale on the cellular side." On the role of human genetics: "If you look at variation in a population scale, you can start to see associations and say, 'Oh, changes in this gene correspond to changes in body mass, or to Alzheimer's risk or to an inflammatory disease.' And because the genetics comes first, it's by definition causal." Check out the link below to read more of Daphne's conversation with The Washington Post and learn how insitro is advancing a pipeline of validated first-in-class drug candidates for multiple diseases toward the clinic. washingtonpost.com/wp-intell…

insitro is excited to return to the Milken Institute Global Conference. On May 3, CFO/CBO Mary Rozenman joins Alex Azar, Jake Becraft, Robert Nelsen & Sung Hee Choe for a discussion on sustaining global leadership in biomedical innovation. We’re excited to connect with leaders in science, health, policy, finance, and philanthropy at #MIGlobal again this year. milkeninstitute.org/events/g…

Tomorrow @insitro presents at @AllofUsResearch Science Day: new work bridging @uk_biobank and All of Us through AI-based phenotype imputation, powered by our Virtual Human™. The research strengthens the genetic evidence for IRS1, a master regulator of liver fat and fibrosis – and the basis for CTRO-1013, our liver-targeted GaINAc siRNA therapy entering the clinic this year. Register: bit.ly/SciDayInvite

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: @insitro CEO @DaphneKoller on how AI is hitting “escape velocity” for finding causal targets for disease and speeding up drug development. Full video: biotechtv.com/post/insitro-j…

Today we announced Joe Hand as insitro’s Chief People Officer. Joe brings a wealth of experience in scaling life sciences organizations, including serving as CHRO and Executive Committee member at Celgene, where he led global talent strategy through significant growth and major transactions. As we advance our AI-driven discovery platform and move programs toward the clinic, Joe will lead our global people strategy to support insitro’s next phase of growth. Welcome to the team, Joe! Read more: insitro.com/news/insitro-app…